

# i2a News



# New Visual identity for i2a







After 12 years it is time for a new visual identity for i2a. The new globe-shaped logo expresses the worldwide character of i2a whereas the colour palette emphasises

the green credentials (REACH compliance / no environmental issues) of our antimony substances.

#### 'i2a member' label



This label has been filed as a Trademark for protection in all relevant countries and can be put by the i2a members on their

paperwork and packaging. While it is not a quality label, it does show which antimony suppliers take EHS issues seriously by paying their fair share of the regulatory cost. It will serve to distinguish the responsible companies from the free riders.

# 5 dossiers REACH registered this year: ahead of the 2013 deadline

The members of i2a have decided to have the REACH registration dossiers of the five remaining substances registered by the Lead Registrant by the end of 2012, ahead of the official 2013 or 2018 deadline. These five substances are: sodium antimonate A, antimony pentoxide, antimony tris (ethylene glycolate), antimony trichloride and antimony trisulfide. Antimony pentoxide,

antimony trichloride and sodium antimonate A have already been registered in April-May 2012. The other 2 will follow shortly.

Companies intending to REACH register one of these substances are hereby invited to contact us as soon as possible to discuss the options of obtaining legitimate access to the relevant REACH registration dossiers.

# **Table of Contents**

- New Visual identity for i2a
- 'i2a member' label
- 5 dossiers REACH registered this year: ahead of the 2013 deadline
- Notification of classifications to ECHA.
- New research ongoing
- New membership
- Upcoming events
- i2a contacts

Avenue de Broqueville 12, 1150 Brussels, Belgium Phone: +32 (0) 32 97 60 92 / Fax: +32 (2) 762 82 29

VAT : BE 0894.536.176

#### Notification of classifications to ECHA.

The different classifications for our 10 substances (classified according to their physical state and impurity level) are available on the i2a website. ( Please see our newsletter of June 2011)

All notified classifications were made publicly available by the ECHA on February 2012. We noticed 337 notifications have been made for antimony pentoxide (APO), classifying APO as acutely toxic, skin and/or eye irritant,

STOT SE and/or aquatic toxic. Yet based on our scientific research (and what is in the REACH registration dossier), <u>APO does NOT need to be classified at all.</u> In March 2012 we contacted all SIEF members of APO in order to find out why these severe classifications were notified to ECHA, but until now have no response. Please contact i2a if you see for any of our substances different classifications popping up that are different or in conflict with the ones submitted by i2a.



# **Upcoming events**

#### 2-6 July 2012:

4<sup>th</sup> International Congress: Eurosoil 2012 in Bari

#### 21 Septembre 2012:

i2a conference call meeting for sales people (i2a members only)

#### 14 November 2012:

i2a Board of Directors (BOD) meeting in Brussels

#### 15 November 2012:

i2a General Assembly (GA) meeting in Brussels



# i2a contacts Chair BOD

#### **CA** Rougier

charles-antoine.rougier@sudamin.com +33 (0) 1 4771 1616

#### Chair GA

#### Geert Krekel

geert.krekel@campine.be +32 (0) 1 4601 549

#### **Secretary General**

#### Karine Van de Velde

kvdv@antimony.be +32 (0) 3 297 60 92

### Office Manager

#### Nathalie Francis


Nathalie@antimony.be +32 (0) 2 762 30 93

# Regulatory Scientist

Jelle Mertens

Jelle@antimony.be +32 (0) 2 771 26 68

## **New research ongoing**



1. Dr Claus Hansen (Copenhagen University, Denmark) is conducting a 1-year study (Feb 2012-Feb 2013) on the uptake.

effects and elimination of antimony trioxide (ATO) particles in rat and human lung macrophages. The project aim is to provide more insight into the mechanisms behind ATO effects in rat lungs, and to compare these with human lungs. This way, we might get a better understanding

about the mechanisms behind the carcinogenicity of inhaled ATO particles with rats (and humans).

2. LPT (Hamburg) was contracted to perform the 90-d oral repeated dose toxicity study combined with reproductive toxicity (OECD 408) and the prenatal Developmental Toxicity Study (OECD 414) as proposed in the sodium hexahydroxoantimonate REACH dossier. Dose-range finding studies were performed in May 2012, and reported in June 2012. Final study reports are expected mid October 2012 and January 2013. Results will be read-across to the REACH dossiers of APO and sodium antimonate A (SAA).

# **New membership**

i2a is pleased to announce that the Korea Zinc Company Ltd., and Trademet Sa are the newest members of i2a.

The aim of the members of i2a is to have ALL antimony producers worldwide become member of i2a to be able to deal with international EHS issues together. For this purpose, as of January 2013, companies worldwide (not exporting into Europe) can become member of i2a without having to

buy the scientific REACH data. As i2a is a

non-profit
organisation,
the more
companies join,
the less everybody
pays and the better
i2a can defend the
EHS interests of the
antimony producers
worldwide.

